Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Determined To Improve Image Of HIV Tests After Regulatory Setbacks

This article was originally published in The Gray Sheet

Executive Summary

Applications submitted by African countries for Abbott's Determine rapid HIV diagnostic test will be evaluated by health care consulting firm Axios International at the end of April, Abbott said March 27.

You may also be interested in...



OraSure's OraQuick

CDC selects firm's rapid HIV-1/2 test under treatment investigational device exemption granted by FDA, OraSure announces March 15. CDC is focusing use of test in public hospitals in five U.S. cities for delivery room testing, as well as emergency departments and outpatient clinics. No rapid HIV test currently is marketed in the U.S.; the agency authorized continued use of the investigational test by CDC because it addresses a serious and life-threatening condition for which no alternatives exist. Abbott's SUDS HIV-1 rapid test was temporarily withdrawn from the market due to quality control issues (1"The Gray Sheet" Oct. 23, 2000, p. 24). Trinity Biotech's Feb. 5 premarket approval application for Uni-Gold rapid HIV test is pending at FDA

Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits

A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

UsernamePublicRestriction

Register

MT014665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel